Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Celcuity Inc.

NASDAQ: CELC · Industrial Applications and Services · 4 alerts · CIK 1603454

Share price
$60.57Close, Nov 16
Market cap
$2.98B
Shares outstanding
49.13MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Celcuity Inc. filings on SEC EDGAR ↗

5:16 PM ET 10-Q
Financial Results

Celcuity Q3 2026 Results: Net Loss of $73.3M, Loss Widens

Celcuity Inc. reported a significant increase in total assets to $726.9 million as of September 30, 2026, driven by a substantial rise in investments and the addition of $50 million in intangible assets. The company is preparing for the commercialization of REVTORPYK (gedatolisib) and maintains a strong liquidity position with $642.7 million in cash, cash equivalents, and investments.

Key figure
Net loss $73.3M
4:07 PM ET 8-K
Financial Results

Celcuity Financial Results

Celcuity Inc. reported financial results for the third quarter of 2026, highlighting the commercial launch of REVTORPYK (gedatolisib) on September 30, 2026. The company reported that 91% of U.S. commercial and Medicare lives are covered by health plans for the new treatment, with 78% of top strategic accounts already prescribing the drug.

Term
Q3 2026

“Our commercial and medical affairs teams have laid the foundation for a strong launch over the past few years, and their efforts are paying off. Physicians are enthusiastic and eager to treat their patients with REVTORPYK, and we are pleased with their interest in getting eligible patients on treatment in the initial weeks since we launched.”

Brian Sullivan, CEO and co-founder of Celcuity
8:05 AM ET 8-K
Leadership Change

Celcuity Leadership Change

Celcuity Inc. has appointed David W. Gryska to its Board of Directors, effective October 1, 2026, increasing the board size to nine members. Mr. Gryska, a former CFO of Incyte and Celgene, will also serve on the Audit and Compensation Committees. His appointment comes as the company transitions to a commercial-stage entity following its first FDA approval for REVTORPYK.

Counterparty
David W. Gryska
8:05 AM ET 8-K
Product Launch

Celcuity Product Launch

Celcuity Inc. announced the commercial availability of REVTORPYK™ (gedatolisib) in the United States for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation. The therapy, which was FDA-approved in July 2026, is the first to inhibit all class I PI3K isoforms and mTOR complexes to blockade the PAM pathway. The company has also launched the REVTORPYK Support Services program to assist with patient access and financial assistance.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.